Clariane Shares Drop 2.3% and Fall Below Key Moving Averages
Clariane fell by 2.3% this Wednesday, March 11, to 3.83 euros, amid a widespread decline in European stock markets. The stock is now trading below its 20-day and 50-day moving averages, both positioned at 3.89 euros. BNP Paribas Exane has recently adjusted its price target on the stock.
During the session, Clariane is trading at 3.83 euros, down 2.3% from the previous close of 3.92 euros. The stock has thus fallen below its 20-day and 50-day moving averages, both at 3.89 euros, indicating a weakening of the short-term upward momentum. The price is also approaching the support threshold at 3.74 euros; a downward breach of this level could increase selling pressure. The Relative Strength Index (RSI), which measures the relative strength of the ongoing movement, stands at 45, indicating a neutral zone but with a downward orientation. This level does not signal an oversold condition but confirms the lack of buying support at this stage. It is worth noting that the nearest resistance is at 4.07 euros, a level the stock has recently failed to surpass. This decline is part of a challenging session for European markets: the CAC 40 is down 0.49%, while the DAX has lost 0.94% and the FTSE 100 is down 0.81%. The SBF 120, which includes Clariane, is down 0.52%.
Recent Analyst Adjustment
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
On March 9, BNP Paribas Exane lowered its price target on Clariane from 4.90 euros to 4.70 euros, while maintaining an 'outperform' rating. At the current price of 3.83 euros, this target implies a potential revaluation of about 22.7%. Over the past year, the stock has still posted an increase of 8.01%, despite a slight decline of 0.98% over the last seven days. The quarterly performance remains almost stable at +0.52%. Upcoming financial milestones likely to provide new insights include the publication of the first quarter 2026 revenue, scheduled for April 23, followed by the annual general meeting planned for May 12.
SectorSanté · Etablissements de santé / EHPAD›Etablissements de santé
Context
Period
Period: 1T2026
Key reported figures
Revenue: 1336M€
Guidance from the release
Avec une croissance organique de 4,9 %, le premier trimestre 2026 s’inscrit pleinement dans la dynamique.
Le chiffre d’affaires au 31 mars 2026 s’établit à €1 336m, en progression de +4,9%.
Risks mentioned
Impact des cessions intervenues en 2025 dans le cadre du plan de renforcement.
Risque lié aux conditions de marché futures.
Effets des défis réglementaires dans le secteur.
Opportunities identified
Lancement d'une obligation senior de €500m à échéance 2031.
Nouvelle dynamiqueprix/volume grâce aux mesures d’adaptation mises en place.
Engagement fort des collaborateurs pour atteindre les objectifs opérationnels.
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.